PROBIOMED STRENGHTENS ITS DERMOCOSMETIC PORTFOLIO
Together with LG Chem, PROBIOMED brings to the Mexican market 3 new presentations of facial fillings with cross-linked hialuronic acid, now with lidocaine.
Mexico City, August 1st, 2018 – From July 27th to 29th, more than 65 aesthetic doctors, dermatologists and plastic surgeons gathered in Puerto Vallarta to be part of the launch of the new line of cross-linked hialuronic acid with lidocaine which joins the aesthetic medicine portfolio of PROBIOMED, composed until now by cross-linked hialuronic acid and botulinum toxin type A.
As part of the event, they attended a conference in which Jaime Uribe Wiechers -PROBIOMED’s CEO-, Carlos Domínguez Cruces –Private Market Commercial Director- and Jorge Bächtold Sotelo –Business Development Manager- led the launch and presented doctors Lucía Achell Nava, Salvatore Piero Fundaro and Edgar Jair Carranco, who shared with their colleagues their experience in expression lines correction and volume effects using the new products. Besides, they participated in a talk about social media management in aesthetic medicine which was taught by David Gaona, digital strategist and founder of the Mexican Association of Digital Marketing and Social Media Professionals (PROSOMEX, A.C.).
The hyaluronic acid-based line of products that PROBIOMED markets as a license of the Korean company LG Chem; is available throughout Mexico for health professionals and this way the Mexican biopharmaceutical strenghtens its competitiveness in the aesthetic market.
About PROBIOMED
PROBIOMED is a Mexican biopharmaceutical company focused on research, development, manufacture and commercialization of pharmaceutical products for human health. We employ more than 800 men and women and operate 3 manufacturing facilities that comply with the strictest national and international regulation.
Since our establishment, in 1970, we have worked to provide millions of people around the globe with high-technology and affordable solutions that help improve health and quality of life. Our portfolio is composed of a wide range of chemical synthesis generics and high-tech biosimilars for the prevention and treatment of autoimmune and chronic-degenerative diseases, hematological and metabolic disorders, as well as malignant neoplasms, among other conditions.
About LG Chem
Founded in the Republic of Korea in 1947, as part of the group of leading electronic enterprises, LG Chem is today one of the most important companies in the Korean chemical industry and has built a global productions, sales and R&D network throughout the major cities of the world.
LG Chem is committed to becoming a global company with the vision of “growing with customers by providing innovative materials and solutions”; in this sense, it stands out the fact that for almost 30 years it has been focused on the research, development and commercialization of hialuronic acid-based products which are currently leaders in Korea and among the preferred by Mexican physicians.
